Uncategorised
09 Apr 2021
Coronavirus company news summary – J&J vaccine US allocations down 85% amid uneven production – Lilly/Incyte’s baricitinib misses primary endpoint in Phase III trial in hospitalised Covid-19 patients
According to the Centers for Disease Control and Prevention (CDC), the US government will allocate approximately 85% fewer doses of Johnson & Johnson’s Covid-19 vaccine to states next week due…
08 Apr 2021
Coronavirus company news summary – Moderna vaccine-elicited antibodies found to persist at six months – NIAID investigates allergic reactions to Moderna and Pfizer/BioNTech vaccines
Moderna has highlighted the publication of antibody persistence data out to six months following the second dose of the Moderna Covid-19 Vaccine. The study evaluated 33 healthy adults in a…
07 Apr 2021
Coronavirus company news summary – AZ vaccine trial in under-18s paused as regulators investigate blood clot link – Catalent to provide new vial filling capacity for Moderna Covid-19 vaccine
The University of Oxford stated that it has stopped a small UK trial that involved the use of its Covid-19 vaccine developed with pharmaceutical company AstraZeneca in children and teenagers.…
06 Apr 2021
Coronavirus company news summary – Novavax starts crossover arms in Covid-19 vaccine trials – FDA gives positive opinion on Tetra’s investigational therapy for Covid-related inflammation
Novavax has initiated crossover arms in two of its ongoing trials of NVX-CoV2373, the company’s Covid-19 vaccine candidate. Crossover ensures the administration of the vaccine to all participants in the…
01 Apr 2021
Coronavirus company news summary – Pfizer/BioNTech Covid-19 vaccine shows 100% efficacy in adolescents – Moderna’s B.1.351 variant vaccine starts trial in adult volunteers
Pfizer and BioNTech have announced positive topline results from a pivotal Phase III trial of BNT162b2, their Covid-19 vaccine, in adolescents aged between 12 and 15 years who may or…
31 Mar 2021
Coronavirus company news summary – Celonic to produce 100 million CureVac jabs at German plant – Tetra gets Health Canada nod to apply for trial of cannabinoid-based Covid-19 treatment
Contract manufacturing organisation Celonic has signed an agreement with CureVac to produce 100 million doses of the latter’s mRNA-based Covid-19 vaccine candidate, CVnCoV. More than 50 million doses are expected…
